BDX rises as investors revisit raised FY26 outlook and buyback actions after Q2 beat

Becton, Dickinson and Company (BDX) is up 3.2% today. Here is some analysis on what might have caused this price movement.

Analysis: The move looks most consistent with investors leaning back into BD’s post-earnings narrative: a fiscal Q2 beat, higher full-year adjusted EPS guidance, and active capital return. With the company also highlighting execution on a large accelerated share repurchase and debt reduction, sentiment may be improving after recent volatility in the name.

Details:

BD reported fiscal 2026 Q2 results (quarter ended March 31, 2026) with revenue growth and adjusted EPS that topped market expectations, alongside an increase to its fiscal 2026 adjusted EPS guidance range.

BD disclosed it executed $2.0 billion of accelerated share repurchases and also retired debt during the quarter, actions that can support per-share earnings and bolster investor confidence.

In recent weeks, at least one major brokerage resumed/reiterated a positive rating with a stated price target, which can help drive incremental buying interest.

Separately, BD’s 10-Q discussed an FDA Warning Letter tied to its El Paso site and a voluntary U.S. ship hold on certain products for additional testing; today’s strength suggests investors may be viewing these items as manageable relative to the earnings outlook.

Sources:

BD Investor Relations, U.S. SEC, Stock Analysis

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$BDX Insider Trading Activity

$BDX insiders have traded $BDX stock on the open market 10 times in the past 6 months. Of those trades, 0 have been purchases and 10 have been sales.

Here’s a breakdown of recent trading of $BDX stock by insiders over the last 6 months:

MICHAEL DAVID GARRISON (EVP & Pres Med.Essntl&BioPharm) has made 0 purchases and 3 sales selling 2,239 shares for an estimated $457,308.
BERTRAM L SCOTT sold 953 shares for an estimated $174,027
MICHAEL FELD (EVP, Chief Revenue Officer) has made 0 purchases and 6 sales selling 448 shares for an estimated $80,860.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive BDX Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$BDX Hedge Fund Activity

We have seen 689 institutional investors add shares of $BDX stock to their portfolio, and 814 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

AUTO-OWNERS INSURANCE CO removed 40,501,260 shares (-99.5%) from their portfolio in Q1 2026, for an estimated $6,303,616,106
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 6,005,889 shares (-37.0%) from their portfolio in Q4 2025, for an estimated $1,165,562,878
VANGUARD GROUP INC added 4,223,149 shares (+13.0%) to their portfolio in Q4 2025, for an estimated $819,586,526
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO removed 4,140,223 shares (-99.6%) from their portfolio in Q1 2026, for an estimated $644,384,307
GENERATION INVESTMENT MANAGEMENT LLP removed 1,984,672 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $385,165,295
JPMORGAN CHASE & CO removed 1,794,165 shares (-33.9%) from their portfolio in Q4 2025, for an estimated $348,193,601
BLACKROCK, INC. removed 1,495,294 shares (-5.4%) from their portfolio in Q1 2026, for an estimated $232,727,558

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$BDX Government Contracts

We have seen $102,942,719 of award payments to $BDX over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

INFUSION PUMPS AND SERVICES: $5,519,658
PHARMACY INPATIENT AUTOMATION SUPPORT - ENTERPRISE MAINTENANCE AND SUPPORT SERVICES: $5,352,302
INFUSION PUMPS MULTIPLE-AWARD IDIQ VISN 10 ORDER: $5,252,124
INFUSION PUMPS: $5,057,297
FLEET REPLACEMENT INFUSION PUMPS: $3,010,650

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$BDX Congressional Stock Trading

Members of Congress have traded $BDX stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $BDX stock by members of Congress over the last 6 months:

REPRESENTATIVE KEVIN HERN sold up to $50,000 on 03/17.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$BDX Price Targets

Multiple analysts have issued price targets for $BDX recently. We have seen 13 analysts offer price targets for $BDX in the last 6 months, with a median target of $180.0.

Here are some recent targets:

Matt Miksic from Barclays set a target price of $204.0 on 05/11/2026
Lawrence Biegelsen from Wells Fargo set a target price of $161.0 on 05/08/2026
Joshua Jennings from TD Cowen set a target price of $163.0 on 05/04/2026
Jason Bednar from Piper Sandler set a target price of $159.0 on 04/17/2026
David Roman from Goldman Sachs set a target price of $167.0 on 04/10/2026
David Toung from Argus Research set a target price of $180.0 on 03/23/2026
Joanna Wiensch from Citigroup set a target price of $198.0 on 02/11/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.